# Allogene Therapeutics, Inc.

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/en/companies/Allogene Therapeutics, Inc.).

## Overview

Allogene Therapeutics is a clinical-stage immuno-oncology company developing genetically engineered allogeneic T cell therapies for cancer and autoimmune disease. Its core idea is to create “off-the-shelf” CAR T products derived from healthy donors, so treatment can be delivered faster and at larger scale than autologous cell therapies made from a patient’s own cells. The company’s pipeline is still in development, with management highlighting upcoming clinical readouts expected in 2026 as potential validation points for the platform. Allogene is focused on a small number of lead programs, including cema-cel in large B-cell lymphoma and ALLO-329 in autoimmune disease, while also maintaining collaborations that support its gene-editing and biomarker strategy.

## Products & services

• Off-the-shelf allogeneic CAR T cell product candidates
• cema-cel (cemacabtagene ansegedleucel) for LBCL
• ALLO-329 next-generation CD19 Dagger® program
• ALPHA3, RESOLUTION and TRAVERSE clinical trials
• Gene-editing and multiplex silencing platform collaborations
• Licensing and development partnerships for regional markets

- **Allogeneic CAR T oncology programs** (70%) — Engineered T cell therapies designed to target hematologic cancers such as large B-cell lymphoma and other blood cancers.
- **Autoimmune disease cell therapy programs** (20%) — Allogeneic T cell candidates intended to eliminate pathogenic autoreactive cells in autoimmune disorders.
- **Platform and gene-editing collaborations** (10%) — Licensing and technology partnerships that support next-generation cell engineering and development.

- Off-the-shelf allogeneic CAR T cell product candidates
- cema-cel (cemacabtagene ansegedleucel) for LBCL
- ALLO-329 next-generation CD19 Dagger® program
- ALPHA3, RESOLUTION and TRAVERSE clinical trials
- Gene-editing and multiplex silencing platform collaborations
- Licensing and development partnerships for regional markets

## Customers

Allogene does not sell commercial products today; its current “customers” are primarily clinical trial participants, investigators, and partner organizations that support development and regional rights. In oncology, the company is targeting patients with large B-cell lymphoma and other hematologic malignancies through clinical studies designed to test whether off-the-shelf CAR T can work in community and academic settings. In autoimmune disease, the target population is patients with severe autoimmune conditions where CD19-directed cell therapy could reset pathogenic immune activity. The company also relies on collaborators such as Foresight Diagnostics and its China-region partner structure to enable biomarker development, trial enrollment, and future regional commercialization.

- **Oncology trial patients** (primary) — Patients with hematologic malignancies, especially large B-cell lymphoma, enrolled to test cema-cel and related allogeneic CAR T candidates.
- **Autoimmune disease patients** (primary) — Patients with autoimmune disorders targeted by ALLO-329 and other next-generation CD19 programs to reduce pathogenic autoreactive cells.
- **Clinical trial sites and investigators** (secondary) — Hospitals, cancer centers, and research sites that administer the company’s studies and generate the clinical data needed for regulatory progress.
- **Diagnostic collaborators** (secondary) — Partners such as Foresight Diagnostics that provide MRD testing to identify eligible patients and support trial design.
- **Regional development partners** (secondary) — Entities in greater China, Taiwan, South Korea and Singapore that hold rights to develop and commercialize licensed products in those territories.

- Patients enrolled in oncology trials for large B-cell lymphoma and other cancers
- Patients with autoimmune disease who may benefit from CD19-directed cell therapy
- Clinical investigators and trial sites running ALPHA3, RESOLUTION and TRAVERSE
- Diagnostic and biomarker partners supporting MRD-based patient selection
- Regional licensing and joint-venture partners in greater China and nearby markets

## Geography

Allogene is headquartered in the United States and conducts most of its development and corporate activity there, including clinical planning, R&D, and regulatory work. The company’s commercial geography is still limited because it has not yet launched a marketed product, but its strategic footprint extends into Asia through a licensing structure covering greater China, Taiwan, South Korea and Singapore. Management also highlighted expansion of ALPHA3 clinical activity into Canada and Australia, and possible EU/UK development work with Foresight Diagnostics, which broadens the trial footprint beyond the U.S. Geography matters because the company’s future value depends on regulatory approvals, trial execution, and partner performance across multiple jurisdictions rather than on current product sales.

- United States is the main operating base for R&D and corporate functions
- Clinical development is centered in U.S. oncology and autoimmune programs
- Greater China, Taiwan, South Korea and Singapore are covered by a licensing territory
- Canada and Australia are being added for ALPHA3 trial expansion
- EU and UK development may be supported through the Foresight collaboration
- International execution matters because approvals and trial logistics differ by region

## Strategy

Allogene’s strategy is to prove that allogeneic, off-the-shelf CAR T can be safer, more scalable, and more practical than autologous cell therapy. Management is concentrating resources on a few core clinical programs, especially ALPHA3 in large B-cell lymphoma and ALLO-329 in autoimmune disease, rather than spreading capital across a broad pipeline. The company is also using partnerships to de-risk key dependencies, including MRD testing with Foresight Diagnostics and gene-editing capabilities through third-party technology agreements. A major near-term objective is to generate clinical readouts that can validate the platform and support future regulatory and commercial planning.

- **Generate decisive clinical data in 2026** (short-term) — The company needs readouts that demonstrate biologic activity, safety, and feasibility of standardized allogeneic CAR T therapy.
- **Advance cema-cel in LBCL** (medium-term) — Large B-cell lymphoma is the most advanced and commercially visible oncology opportunity in the pipeline.
- **Build a scalable autoimmune franchise** (medium-term) — Autoimmune disease could broaden the addressable market and diversify the company beyond oncology.
- **Reduce platform and partner dependency risk** (short-term) — The company relies on external technologies and collaborators for gene editing, diagnostics, and regional rights.

- Focus capital on a small number of lead programs with the highest value potential
- Use upcoming clinical readouts to validate the allogeneic CAR T platform
- Advance cema-cel in first-line LBCL through the ALPHA3 trial
- Develop ALLO-329 for autoimmune disease with simpler or chemotherapy-free lymphodepletion
- Expand trial geography to improve enrollment and support broader regulatory paths
- Leverage diagnostic and gene-editing partnerships to strengthen development execution

## Risks

Allogene faces the classic risks of a clinical-stage biotech company: no approved products, ongoing losses, and a need for substantial additional financing to fund development. Its lead programs are based on novel allogeneic cell therapy technology, so clinical outcomes, safety signals, and regulatory expectations are difficult to predict and could materially delay or derail commercialization. The company is also dependent on third parties for key technologies, clinical trial execution, and diagnostic support, which increases execution risk and reduces control over timelines. In addition, competition is intense in both oncology and autoimmune cell therapy, and larger or better-funded rivals could reach the market first or develop more effective and convenient therapies.

- **Need for substantial additional financing** [high] — The company has recurring losses and must fund expensive clinical development before any product revenue exists.
- **Clinical and regulatory failure of lead programs** [critical] — ALPHA3, RESOLUTION, TRAVERSE and ALLO-329 are still in development, and novel cell therapies can fail on efficacy or safety.
- **Dependence on third-party licensors and collaborators** [high] — The company relies on Cellectis, Servier, Foresight Diagnostics and others for essential technology and trial support.
- **Competition in CAR T and autoimmune cell therapy** [high] — Rivals may develop safer, more effective, or faster-to-market therapies and capture physician adoption first.
- **Manufacturing consistency and donor variability** [high] — Allogeneic products depend on healthy donor cells and reliable manufacturing processes to ensure consistent product quality.

- Clinical failure risk because the platform is still unproven at commercial scale
- Financing risk because development spending exceeds current revenue generation
- Safety and tolerability risk from engineered T cell therapies
- Regulatory delay risk for U.S. and foreign approvals
- Dependency on third-party technology licensors and collaborators
- Competition from better-funded CAR T and autoimmune cell therapy developers
- Manufacturing and donor-variability risk for allogeneic cell products
- Companion diagnostic risk if MRD or other testing is required for approval

## Accounting

As a clinical-stage biotech, Allogene’s reported results are heavily shaped by judgmental accruals rather than product sales. The company specifically highlights accrued research and development costs, stock-based compensation, leases, and impairment of long-lived assets as critical accounting areas, which means reported expenses can move materially as estimates are updated. Collaboration revenue is currently limited and has been tied to the Overland license arrangement, so revenue recognition depends on the timing and satisfaction of performance obligations rather than product shipments. Investors should also watch for quarterly volatility in R&D expense because clinical trial activity, manufacturing work, and partner invoices can create uneven accrual adjustments from period to period.

- **Accrued research and development costs** — Affects R&D expense and accrued liabilities
- **Collaboration revenue recognition** — Affects reported revenue and comparability across periods
- **Stock-based compensation** — Affects R&D and G&A expense
- **Impairment of long-lived assets** — Can create non-cash charges in operating expense

- Accrued R&D costs affect reported operating expense and liabilities
- Collaboration revenue depends on license and performance obligation timing
- Stock-based compensation can materially affect G&A and R&D expense
- Lease accounting affects operating expense and balance sheet liabilities
- Impairment of long-lived assets can create non-cash charges when programs change
- Quarterly expense volatility is driven by clinical trial and manufacturing timing

---

*Last updated: 2026-08-11T04:46:20.054734+00:00*